MNPHARM
White Bear Lake
About MNPHARM
MNPHARM molecular farming combines technology advances in plant microbial genetic engineering, protein purification and controlled indoor agriculture to provide rapid access to affordable recombinant proteins. MNPHARM is dedicated to producing human recombinant proteins needed in the field known as “Regenerative Medicine” to assist therapeutic development by lowering the cost of these proteins to the research community using our proprietary plant based protein expression methods. Recombinant Human Bone Morphogenetic Protein 2 (rhBMP-2) is one of the proteins we produce and is shown to stimulate the production of bone, tissue and cartilage. MNPHARM is able to consistently express and purify large amounts of human recombinant BMP-2 at a purity of 97%+. Compared to other means of protein production, our proprietary expression methods offers the lowest overall cost, short production times and exceptionally high quality.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $400.0K
- Last round: Series Unknown (Jun 2023)
- Website: mnpharm.com
- Phone: 6517567239
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/mnpharm-81871 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.